ascopubs.org5d
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma A total of 121 patients (previous ICI-treated cohort, n = 31, and each of ...
ascopubs.org6d
Mental health monitoring in clinical trials for FDA-approved genitourinary cancer treatments: A decade review.
Evaluating cost-effectiveness in the evolving treatment landscape for metastatic urothelial carcinoma.
ascopubs.org6d
Biomarker testing patterns among patients newly diagnosed with prostate cancer in a community oncology network.
Transcriptional profiling of patients with metastatic hormone-sensitive prostate cancer to uncover specific signatures linked to the transition from androgen-dependent to androgen-independent ...
ascopubs.org6d
Additivity and the efficacy of immune checkpoint blockade-based combination regimens in urothelial cancer.
Feasibility and safety results from RAD-IO: A multi-stage trial of durvalumab (Medi4736) with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer.
ascopubs.org6d
Innovative diagnostic approaches: Serum protein markers in renal cell carcinoma.
Systemic therapies in renal cell carcinoma with brain metastases: A comparative meta-analysis of immunotherapy and tyrosine kinase inhibitors. PSMA-positive tumor vessels around renal cell carcinoma ...
ascopubs.org6d
Reduction of systemic chemotherapy by primary retroperitoneal lymph node dissection in low volume metastatic seminoma.
Validation of new prognostic factors for relapse in patients with clinical stage I seminoma. Time to real-world progression (TTrwP) among patients (pts) with relapsed/refractory (R/R) testicular germ ...
ascopubs.org6d
Characterization of circulating tumor DNA (ctDNA) burden and its association with real-world overall survival among prostate cancer (PC) patients.
Utility of extended interval dosing of denosumab in patients with metastatic prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does ...
ascopubs.org6d
Evaluation of systemic therapy and surgical consolidation in patients with node positive upper tract urothelial carcinoma.
A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2).
ascopubs.org6d
Outcomes of patients with stage I testicular cancer following orchidectomy with borderline retroperitoneal lymph node enlargement at diagnosis.
Outcomes with tandem or triplet autologous stem cell transplant for refractory germ cell tumors. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does ...
ascopubs.org6d
Predicting long term outcomes following radical prostatectomy using a validated pathology-based multimodal artificial intelligence biomarker.
Real-world U.S. county-level analysis of erectile dysfunction diagnosis following radiation therapy for localized prostate cancer: The impact of rectal spacer utilization. This is an ASCO Meeting ...
ascopubs.org1d
Management of relapsed primary retroperitoneal (RP) germ-cell tumor (GCT) after front-line chemotherapy.
Therapeutic approaches and outcomes in patients aged 50+ with germ cell tumours. Survival outcomes by salvage chemotherapy received.
ascopubs.org6d
Decipher risk stratification of radiorecurrent prostate cancer: Correlative analysis of the F-SHARP trial of salvage reirradiation.
Germline correlates of clinical outcomes in aggressive prostate cancer subtypes treated with radiation therapy. Targeting highly aggressive ductal prostate tumours with poly ADP ribose polymerase ...